The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MDS 2020 | Transfusion-dependant, low-risk MDS: what are the options?
Valeria Santini, MD, University of Florence, Florence, Italy, discusses the therapy options for transfusion-dependent, low-risk myelodysplastic syndromes (MDS) patients. Specifically, the stimulation of erythropoiesis with the TGF-β targetting galunisertib and the ligand-trapping luspatercept and sotatercept is outlined. This interview was recorded during an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
